UroGen Pharma (URGN) Receivables - Net (2016 - 2026)
UroGen Pharma's (URGN) quarterly Receivables - Net came in at $55.4 million in Q1 2026, up 182.17% YoY from $19.6 million in Q1 2025, and up 67.5% on a QoQ basis from $33.1 million in Q4 2025.
UroGen Pharma (URGN) Receivables - Net (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Receivables - Net data on file, last reported at $55.4 million in Q1 2026.
- Quarterly Receivables - Net rose 182.17% year-over-year to $55.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.4 million (up 182.17% YoY) and the FY2025 annual result came in at $33.1 million, up 62.95% from the prior year.
- Receivables - Net advanced to $55.4 million in Q1 2026, from $33.1 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $55.4 million in Q1 2026 to a low of $9.4 million in Q3 2022.
- A 5-year average of $18.9 million and a median of $15.5 million in 2023 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2025 — Receivables - Net dropped 13.59% — and 2026, when it surged 182.17%.
- Tracing URGN's Receivables - Net over 5 years: stood at $12.7 million in 2022, then advanced by 21.56% to $15.4 million in 2023, then jumped by 31.46% to $20.3 million in 2024, then surged by 62.95% to $33.1 million in 2025, then soared by 67.5% to $55.4 million in 2026.
- The last three Receivables - Net figures came in at $55.4 million (Q1 2026), $33.1 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.76 Mn |
| Jun 30, 2026 | 88.76 Mn |
| Mar 31, 2026 | 55.41 Mn |
| Mar 31, 2026 | 55.41 Mn |
| Dec 31, 2025 | 33.08 Mn |
| Dec 31, 2025 | 33.08 Mn |
| Sep 30, 2025 | 19.70 Mn |
| Sep 30, 2025 | 19.70 Mn |
| Jun 30, 2025 | 19.65 Mn |
| Jun 30, 2025 | 19.65 Mn |
| Mar 31, 2025 | 19.64 Mn |
| Mar 31, 2025 | 19.64 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Sep 30, 2024 | 22.80 Mn |
| Sep 30, 2024 | 22.80 Mn |
| Jun 30, 2024 | 17.42 Mn |
| Jun 30, 2024 | 17.42 Mn |
| Mar 31, 2024 | 14.16 Mn |
| Mar 31, 2024 | 14.16 Mn |